Serina Therapeutics Hosts Webinar on Parkinson’s Disease Treatment
News related to:Serina Therapeutics · 1 min read
HUNTSVILLE, AL, Sept. 23, 2026 /CourierPR/ -- Serina Therapeutics, a clinical-stage biotechnology company, is set to host a webinar event on Thursday, September 24, 2026, featuring a presentation by its CEO, Steven Ledger.
Currently, an estimated 10 million people worldwide are living with Parkinson’s disease, a condition that has seen no major clinical advances in over 50 years. Serina Therapeutics is at the forefront of this field, developing its proprietary POZ Platform™ drug optimization technology to improve the efficacy and safety of drug products for neurological diseases and other indications.
During the webinar, participants will have the opportunity to engage directly with Steven Ledger, the CEO of Serina Therapeutics. The event is scheduled to commence at 8:30 a.m. Pacific Standard Time (11:30 a.m. Eastern Time) and will be hosted by John F. Heerdink, Jr., the Managing Member of Tribe Public LLC.
Tribe Public LLC, based in San Francisco, California, is a distinguished organization that facilitates corporate-sponsored global webinars and in-person meetings across 41 premier event venues throughout the United States. The event is designed to provide direct access to management teams and leading experts, enhancing awareness of their products, achievements, and strategic initiatives.
Serina’s lead program, SER-252 (POZ-apomorphine), is being developed as a long-acting treatment for advanced Parkinson’s disease. The company’s proprietary POZ Platform™ drug optimization technology is designed to enhance the integrated efficacy and safety profile of multiple therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates.
The webinar is open to a wide range of participants, including Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and media professionals. These stakeholders are encouraged to shape the event agenda by submitting speaker and company preferences through Tribe Public’s complimentary “Wish List” process on its website.
Registration for the event is now open at AdvancingParkinsonsDisease.TribePublic.com. Participants are invited to join this important discussion and gain valuable insights into the latest developments in the treatment of Parkinson’s disease.